Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Barclays analyst Andrew Mok maintains DaVita (NYSE:DVA) with a Equal-Weight and lowers the price target from $160 to $149.
B of A Securities analyst Kevin Fischbeck maintains DaVita (NYSE:DVA) with a Underperform and lowers the price target from $...
DaVita reported a ransomware attack affecting 2.7 million patients, posted Q2 earnings above estimates, and authorized a $2 bil...
- SEC Filing
A look at the updated Berkshire Hathaway portfolio after the second quarter, including a new stake in UnitedHealth.
Warren Buffett has requested confidentiality in a new Berkshire Hathaway position. Will investors find out the stock Thursday?
Barclays analyst Andrew Mok maintains DaVita (NYSE:DVA) with a Equal-Weight and lowers the price target from $169 to $160.
DaVita (NYSE:DVA) affirms FY2025 Adj EPS guidance from $10.20-$11.30 to $10.20-$11.30 vs $10.73 analyst estimate..
DaVita (NYSE:DVA) reported quarterly earnings of $2.95 per share which beat the analyst consensus estimate of $2.79 by 5.92 per...
